Selected article for: "influenza segment and NS segment"
Author: Shehata, Mahmoud M.; Kandeil, Ahmed; Mostafa, Ahmed; Mahmoud, Sara H.; Gomaa, Mokhtar R.; El-Shesheny, Rabeh; Webby, Richard; Kayali, Ghazi; A. Ali, Mohamed
Title: A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice
  • Document date: 2019_12_2
    • ID: 15q6qr4z_17
    Snippet: The H1N1pdm09 vaccine virus grew poorly in embryonated chicken eggs compared with growth of previous seasonal H1N1 isolates [20] , resulting in manufacturers struggling to meet demand. To overcome the limitation of replication of the rescued virus, in addition to the HA, and the modified NA, the PB1 segment of H1N1pdm09 strain was used to generate chimeric bivalent 5 + 3 candidate vaccine strain [21] . The developed vaccine seed virus replicated .....
    Document: The H1N1pdm09 vaccine virus grew poorly in embryonated chicken eggs compared with growth of previous seasonal H1N1 isolates [20] , resulting in manufacturers struggling to meet demand. To overcome the limitation of replication of the rescued virus, in addition to the HA, and the modified NA, the PB1 segment of H1N1pdm09 strain was used to generate chimeric bivalent 5 + 3 candidate vaccine strain [21] . The developed vaccine seed virus replicated well without any associated adaptive mutations. Previous studies indicated that the insertion of reporter genes into the influenza viral NS, M, or NA-encoding segment was successful [22, 23] . The inserted reporter genes in influenza viral genome were associated with inconstant expression levels and genome instability to dispose the foreign insertion. Our strategy of insertion of the short immunogenic peptide after 48 aa in the NA-coding region improved virus replication.

    Search related documents:
    Co phrase search for related documents
    • candidate vaccine and chimeric bivalent: 1, 2
    • candidate vaccine and demand meet: 1, 2
    • candidate vaccine and developed vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • candidate vaccine and expression level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • candidate vaccine strain and developed vaccine: 1, 2, 3
    • demand meet and developed vaccine: 1, 2, 3, 4, 5
    • demand meet and expression level: 1
    • developed vaccine and expression level: 1, 2
    • expression level and foreign insertion: 1